Medicine and Dentistry
Health Care Cost
100%
Cost-Effectiveness Analysis
83%
Chronic Obstructive Pulmonary Disease
63%
Quality Adjusted Life Year
41%
Diseases
25%
Quality of Life
24%
Primary Health Care
23%
Personalized Medicine
23%
Disease Management
21%
Medicine
20%
Maturity Onset Diabetes of the Young
19%
Multiple Chronic Conditions
18%
Asthma
18%
Systematic Review
18%
Congestive Heart Failure
16%
Technology Assessment
16%
Health Care
16%
Standard Gamble
13%
Rating Scale
13%
Health Technology
13%
Inflammatory Arthritis
12%
Rheumatoid Arthritis
12%
Malignant Neoplasm
11%
Diabetes
11%
Frail Elderly
11%
Ankylosing Spondylitis
11%
Chronic Disease
11%
Obstructive Airway Disease
11%
Entrectinib
11%
Decision Making
10%
Health System
9%
Social Participation
9%
Social Interaction
9%
Outpatient
9%
Patient Care
8%
Lifespan
8%
Symptomatic Treatment
8%
Cohort Analysis
8%
Subgroup Analysis
8%
Rheumatology
7%
Glycogen Storage Disease Type II
7%
Functional Status
7%
Health Status
6%
Psychological Well-Being
6%
Health Outcomes
6%
Disease Burden
6%
Cluster Randomized Trial
5%
Cardiovascular Disease
5%
Propensity Score Matching
5%
Utility Assessment
5%
Nursing and Health Professions
Cost Effectiveness Analysis
69%
Obstructive Lung Disease
45%
Quality Adjusted Life Year
34%
Multiple Chronic Conditions
33%
Economic Evaluation
24%
Patient Care
22%
Primary Medical Care
20%
Quality of Life
20%
Health Care Quality
19%
Patient Preference
19%
Disease Management
19%
Asthma
18%
Diseases
18%
Health Economics
18%
Physiotherapy
17%
Practice Guideline
17%
Literature Review
16%
Congestive Heart Failure
16%
Rating Scale
15%
Health Care Personnel
14%
Cost Control
14%
General Practitioner
13%
Biomedical Technology Assessment
13%
Health Outcomes
12%
Manipulative Medicine
11%
Neck Pain
11%
Entrectinib
11%
Ankylosing Spondylitis
11%
Non Insulin Dependent Diabetes Mellitus
11%
Frail Elderly
11%
Malignant Neoplasm
11%
Fibromyalgia
11%
Home Care
9%
Health Care
9%
Cost Benefit Analysis
8%
Palliative Therapy
8%
Insulin Dependent Diabetes Mellitus
8%
Systematic Review
8%
Health Status
8%
Prevalence
7%
Rehabilitation Engineering
7%
Outpatient
7%
Outpatient Department
6%
Health Care Delivery
6%
Patient with Asthma
6%
Mental Health
6%
Meta Analysis
6%
Health Care Cost
6%
Clinical Outcome
6%
Confidence Interval
6%
Pharmacology, Toxicology and Pharmaceutical Science
Diseases
49%
Chronic Obstructive Lung Disease
44%
Rheumatoid Arthritis
27%
Asthma
27%
Inflammatory Arthritis
27%
Congestive Heart Failure
27%
Bronchodilating Agent
16%
Monotherapy
12%
Functional Status
11%
Obstructive Airway Disease
11%
Olodaterol
11%
Acute Disease
11%
Placebo
11%
Glaucoma
11%
Airway Obstruction
8%
Disease Exacerbation
7%
Dyspnea
7%
Health Status
7%
Pharmacoeconomics
6%
C Reactive Protein
6%
Malignant Neoplasm
6%
Arthralgia
5%
Non Insulin Dependent Diabetes Mellitus
5%
Entrectinib
5%
Alglucosidase Alfa
5%
Receptor Agonist
5%
Fluticasone
5%
Clinical Trial
5%
Chemotherapy
5%
Cerebrovascular Accident
5%
Interstitial Lung Disease
5%
Fluticasone Propionate
5%
Phosphotransferase
5%
Sacubitril Plus Valsartan
5%
Cohort Study
5%
Pharmacotherapy
5%
Glycogen Storage Disease Type 2
5%
Disease Activity
5%
Carcinoembryonic Antigen
5%
Angiotensin Receptor
5%
Fluoropyrimidine
5%
Methotrexate
5%
Intraocular Hypertension
5%
Cholinergic Receptor Blocking Agent
5%
Ankylosing Spondylitis
5%
Enkephalinase Inhibitor
5%
Replacement Therapy
5%
Valsartan/Sacubitril
5%
Metastatic Breast Cancer
5%
Biological Marker
5%
